TNP1 and cancer: Fifty-eight of the 75 antigens were reactive with the screening sera; 13 of these were reactive with sera from both normal donors and cancer patients, and 4 other antigens (KP-OVA-25/TBL2, KP-OVA-35/TNP1, KP-OVA-68/C16orf42 and KP-OVA-73/S100A4) reacted exclusively with sera from cancer patients (ranging from 15% to 30%) (Table III).